Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Urologic Diseases » Kidney Diseases
Diseases [C] » Urogenital Diseases [C12] » Male Urogenital Diseases » Urologic Diseases » Kidney Diseases
Diseases [C] » Urogenital Diseases [C12] » Urologic Diseases » Kidney Diseases
Hierarchy View
Subtype Terms (26)
AIDS-Associated Nephropathy
5 approved drugs
Chronic Kidney Disease-Mineral and Bone Disorder
126 drugs (80 approved, 46 experimental)
Diabetes Insipidus
11 drugs (9 approved, 2 experimental)
Diabetic Nephropathies
179 drugs (88 approved, 91 experimental)
Hepatorenal Syndrome
11 drugs (8 approved, 3 experimental)
Hydronephrosis
5 approved drugs
Hyperoxaluria
33 drugs (11 approved, 22 experimental)
Hypertension, Renal
9 drugs (5 approved, 4 experimental)
Kidney Diseases, Cystic
1 approved drug
Kidney Neoplasms
308 drugs (157 approved, 151 experimental)
Nephritis
17 drugs (12 approved, 5 experimental)
Nephrocalcinosis
3 drugs (2 approved, 1 experimental)
Nephrolithiasis
52 drugs (38 approved, 14 experimental)
Nephrosclerosis
1 experimental drug
Nephrosis
2 drugs (1 approved, 1 experimental)
Renal Artery Obstruction
18 drugs (13 approved, 5 experimental)
Renal Insufficiency
271 drugs (184 approved, 87 experimental)
Renal Tubular Transport, Inborn Errors
Uremia
14 drugs (10 approved, 4 experimental)
Zellweger Syndrome
7 drugs (6 approved, 1 experimental)
Phase 3 Indicated Drugs (64)
Phase 2 Indicated Drugs (91)
Phase 1 Indicated Drugs (86)
Other Experimental Indicated Drugs (52)
Organization Involved with Phase 4 Indications (322)
Albany College of Pharmacy and Health Sciences
Anhui College of Traditional Chinese Medicine
Aristotle University of Thessaloniki
CardioVascular Research Foundation, Korea
Centers for Disease Control and Prevention, China
Centro de Investigación Biomédica de Michoacán
China Academy of Chinese Medical Sciences
Chinese Academy of Medical Sciences
Chinese Center of Diseases Control and Prevention
Chinese University of Hong Kong
Chronic Liver Disease Foundation
Coney Island Hospital, Brooklyn, NY
Effice Servicios Para la Investigacion S.L.
Emerio & Lourdes Linares Research and Education Center
Federal University of Rio Grande do Sul
Florida Heart Research Institute
Fundação de Amparo à Pesquisa do Estado de São Paulo
Heilongjiang University of Traditional Chinese Medicine
Hospital Alessandro Manzoni Lecco
Hospital General de México Dr. Eduardo Liceaga
Hospital General de Zona N° 83 Instituto Mexicano del Seguro Social.
Hospital General Regional N° 1 Instituto Mexicano del Seguro Social.
Hospital Universitario Arnau de Vilanova de Lleida
Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
I.M. Sechenov First Moscow State Medical University
Institute for Health Outcomes and Process Evaluation Reseach
Instituto Dante Pazzanese de Cardiologia
Isala Clinics, Zwolle, The Netherlands
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.
Justus Liebig University Giessen
Medical Research Foundation, The Netherlands
Memorial University of Newfoundland
Methodist Cancer Center, Houston, Texas
Mt. Sinai Medical Center, Miami
National Cheng Kung University
National Health and Medical Research Council, Australia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health (NIH)
National Kidney and Transplant Institute, Philippines
National University of Malaysia
NephroNet Clinical Research Consortium
Ningbo Yinzhou People's Hospital
Oregon Health and Science University
Ospedale Misericordia e Dolce, Prato
People's Liberation Army of China
Second Military Medical University
Shaanxi University of Chinese Medicine
Shanghai Ruijin Hospital North
Shin Kong Wu Ho-Su Memorial Hospital
Sociedad Andaluza de Trasplantes de Organos y Tejidos
Southeast Renal Research Institute
State University of New York, Brooklyn
State University of New York, Buffalo
State University of New York, Syracuse
Steno Diabetes Center Copenhagen
St. Marianna University School of Medicine
Taipei Veteran General hospital
Technical University of Munich
Tianjin TongRenTang Group Co., Ltd.
Université catholique de Louvain
University of Alabama, Birmingham
University of British Columbia
University of Campania Luigi Vanvitelli
University of Colorado, Boulder
University of Colorado, Denver
University of Erlangen-Nuremberg
University of Modena and Reggio Emilia
University of Naples Frederico II
University of North Carolina at Chapel Hill
University of Roma La Sapienza
University of Southern Denmark
University of Texas, Arlington
University of Western Australia
Virginia Commonwealth University
Vita-Salute University of Milano. Italy
Organization Involved with Phase 3 Indications (233)
1st People's Hospital of Foshan
American Society of Nephrology
Azienda Ospedaliero-Universitaria Consorziale
Badalona Hospital Germans Trias i Pujol
Boryung Pharmaceutical Company
Canadian Institutes of Health Research (CIHR)
Caritas Teaching Hospital, Bucharest
Carol Davila University of Medicine and Pharmacy
Case Western Reserve University
Centre Hospitalier Departemental Vendee
Centre Hospitalier Universitaire de Nīmes
Corbridge Group Philippines, Inc.
Cyril and Methodius University
Dynavax Technologies Corporation
East Kent Hospitals University NHS Foundation Trust
Fondazione Toscana Gabriele Monasterio
Fondo Nacional de Desarrollo Científico y Tecnológico, Chile
GeneScience Pharmaceuticals Co., Ltd.
Geniko Nosokomeio Athinas Ippokrateio
German Atrial Fibrillation Network
Gottfried Wilhelm Leibniz Universität Hannover
Grupo Medifarma, S. A. de C. V.
Guangdong Pharmaceutical University
Hamilton Health Sciences Corporation
Hannover Clinical Trial Center GmbH
Health Research Council, New Zealand
Henan Provincal People's Hospital
Hoosier Cancer Research Network
Hospital El Bierzo, Fuentesnuevas Ponferrada
Hospital general Universitario de Ciudad Real
Hospital General Universitario Gregorio Marañon
Hospital Universitario Fundación Alcorcón
Instituto Nacional de Cardiologia Ignacio Chavez
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Institut Universitaire de Recherche Clinique, RD Nephrologie SAS
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jiangxi Provincial People's Hospital
Kuhnil Pharmaceutical Co., Ltd.
Los Angeles Biomedical Research Institute
Medley Pharmaceutical Industry SA
Moorgreen Hospital, Southampton
National Institute for Health Research, United Kingdom
National Institute of Allergy and Infectious Diseases (NIAID)
National Research Council, Italy
National University of Ireland
National University of Singapore
Office of Dietary Supplements (ODS)
Onassis Cardiac Surgery Centre
Polycystic Kidney Disease Foundation
Postgraduate Institute of Medical Education and Research
Sapporo Higashi Tokushukai Hospital
Sinomune Pharmaceutical Co., Ltd
The Kidney Foundation of Canada
The Physicians' Services Incorporated Foundation
The University of Texas, Dallas
Translational Research Informatics Center, Kobe, Hyogo, Japan
Unidad de Investigacion Medica en Enfermedades Renales
Universidad Autonoma de Madrid
Universidad Complutense de Madrid
University of Applied Sciences Utrecht
University of California, Los Angeles
University of California, San Francisco
University of Texas, Galveston
Organization Involved with Phase 2 Indications (169)
A2 Healthcare Taiwan Corporation
Bangladesh Laser & Cell Surgery Institute & Hospital
Cell Therapy And Technology, S.a. De C.v.
Conselho Nacional de Desenvolvimento Científico e Tecnológico
CRC per le Malattie Rare Aldo e Cele Daccò
DongWha Pharmaceutical Company
Fangshan Hospital of Traditional Chinese Medicine
German Federal Ministry of Education and Research
Global Blood Therapeutics, Inc.
Guangdong Provincial Hospital of Traditional Chinese Medicine
Hospital Universitari de Bellvitge
Institute of Clinical and Experimental Medicine Nephrology Clinic Prague
Medice Arzneimittel Pütter GmbH & Co KG
National Cancer Institute (NCI)
National Center for Complementary and Integrative Health (NCCIH)
National Center for Research Resources (NCRR)
National Health Service, United Kingdom
National Heart, Lung, and Blood Institute (NHLBI)
Sanwa Kagaku Kenkyusho Co., Ltd.
South Texas Health Care System, San Antonio, TX
Taichung Veterans General Hospital
University of Applied Sciences Würzburg-Schweinfurt
University of California, San Diego
University of Illinois at Chicago
University of Nice Sophia Antipolis
University of Southern California
Vascular Pharmaceuticals, Inc.
Organization Involved with Phase 1 Indications (60)
Baodin City Hospital of Traditional Chinese Medicine
California Institute of Renal Research, Inc.
Federal University of Rio de Janeiro
FerruMax Pharmaceuticals, Inc.
Guangzhou Pharmaceucal Company Limited
Hubei University of Chinese Medicine
National Research Council, Brazil
Osprey Pharmaceuticals USA, Inc.
Pharmaceutical Research Associates, Inc. (PRA)
Regenerative Medicine Minnesota
Organization Involved with Other Experimental Indications (98)
Alberta Heritage Foundation for Medical Research
Caribbean Health Research Council
Dalin Tzu Chi General Hospital
"Maggiore della Carità" Hospital
Medical University of South Carolina
Nanjing University of Traditional Chinese Medicine
National Institute of General Medical Sciences (NIGMS)
Nicolaus Copernicus University
Oklahoma Foundation for Digestive Research
Second Okamoto General Hospital
Shanghai Municipal Health Bureau
Shanghai University of Traditional Chinese Medicine
St Georges University NHS Foundation Trust
Technical University of Dresden
The Hong Kong Society of Nephrology
Tsukiwa-machi, Seta, Otsu, Shiga, Japan
Universidad Autonoma de Nuevo Leon
Universidade Federal do Parana
University of California, Davis
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
